Vivo Capital’s Yarrow Bioscience YARW Stock Holding History

Vivo Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-261	Closed	-$1.61M	–	65
2021 Q1	$1.61M	Hold	261	–	–	0.06%	59
2020 Q4	$1.48M	Sell	261 -245	-48%	-$1.54M	0.07%	55
2020 Q3	$3.02M	Sell	506 -506	-50%	-$2.95M	0.17%	56
2020 Q2	$6.3M	Sell	1,012 -56	-5%	-$379K	0.45%	43
2020 Q1	$10.3M	Buy	+1,068	New	+$16.8M	0.93%	33
2019 Q3	–	Sell	-1,114	Closed	-$24M	–	28
2019 Q2	$24M	Hold	1,114	–	–	2.25%	13
2019 Q1	$31.5M	Hold	1,114	–	–	3.14%	10
2018 Q4	$16.5M	Hold	1,114	–	–	2.11%	13
2018 Q3	$39.5M	Hold	1,114	–	–	3.98%	8
2018 Q2	$32.6M	Hold	1,114	–	–	4.2%	6
2018 Q1	$151M	Buy	+1,114	New	+$135M	21.35%	1

Other funds holding YARW

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Vivo Capital's YARW Position: Q2 2021 in Review

Vivo Capital sold out of Yarrow Bioscience (YARW) in Q2 2021, closing a stake of 261 shares — an estimated $1.61M sold.

Vivo Capital first reported a position in YARW in Q1 2018 and held it in 11 quarters. The position peaked at $151M in Q1 2018. 63 funds tracked by Wall St. Rank hold YARW as of Q2 2021.

Vivo Capital reported no remaining Yarrow Bioscience position as of Q2 2021 after selling out during the quarter.
Vivo Capital sold 261 Yarrow Bioscience shares in Q2 2021, an estimated $1.61M.
Vivo Capital first reported a position in Yarrow Bioscience in Q1 2018 and held it in 11 quarters.
Vivo Capital's Yarrow Bioscience position peaked at $151M in Q1 2018.
63 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2021.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.